PHARMACOKINETIC-PHARMACODYNAMIC MODELLING OF SIDE EFFECTS OF NITRENDIPINE
|
|
- Linda Owens
- 6 years ago
- Views:
Transcription
1 PHARMACOKINETIC-PHARMACODYNAMIC MODELLING OF SIDE EFFECTS OF NITRENDIPINE I. Locatelli, I. Grabnar, A. Belič, A. Mrhar, R. Karba, University of Ljubljana, Slovenia Corresponding Author: I. Grabnar Faculty of Pharmacy, University of Ljubljana Aškerčeva 7, 1000 Ljubljana, Slovenia Phone: , Fax: Abstract. The modelling aim in this study was to explore the relationship between plasma concentrations of a cardiovascular drug nitrendipine and occurrences of its side effects. The data were taken from a bioequivalence study in 40 men with a 20 mg single dose of nitrendipine. During the study occurrences of side effects, their severity, onset time and duration were recorded. Overall, side effects occurred in 26 applications. A two compartment pharmacokinetic model with lag time and first order absorption was fitted to plasma concentrations. For a pharmacodynamic part fixed effect model was applied. An indirect link model based on effect compartment was used to connect the pharmacokinetic and pharmacodynamic data. Estimated model parameters of a group with side effects and a group without them were compared. Increased extent and rate of absorption raised the probability for occurrence of side effect. Incidence of side effect was also determined by increased sensitivity to nitrendipine at the site of action. 1. Introduction Pharmacokinetics (PK) describes time courses of drug concentration in body fluids (mainly in plasma or blood) resulting from a certain drug dose and pharmacodynamics (PD) describes the observed effects resulting from a certain drug concentration [3]. Linking these two aspects results in pharmacokineticpharmacodynamic (PK/PD) modelling, which evaluates dose-concentration-response and facilitates description and prediction of the time course of drug effects resulting from a certain dosing regimen [3]. PK-PD models consist of 3 components: - a pharmacokinetic model; characterising time courses of plasma concentrations of the active drug and metabolite, - a pharmacodynamic model; characterising the relationship between drug concentration at site of action and effect, - a link model, which serves to account for the often-observed delay (especially under non steady-state conditions) of the effect relative to the plasma concentration [2]. The observed delay can be a consequence of a much slower distribution of the active drug towards the site of action - biophase. Another kind of delay that can be observed for some drugs is a delay in pharmacological reaction of a certain drug (e.g. warfarin). In this study PK/PD modelling was focused on a safety aspect of a cardiovascular drug nitrendipine. Our aim was to explore the relationship between its plasma concentration and a possibility for occurrence of side effect. In PK/PD modelling of side effects some uncommon problems can be met. Side effects are mainly represented as discrete random variables either in order of magnitude (e.g. slight, moderate, severe pain) or as dichotomous, quantal variable (e.g. pain or no pain) [1]. Another characteristic that has to be addressed is the fact that they are usually observed continuously. This can present many difficulties, since the majority of the PK/PD modelling software is designed to estimate the parameters by fitting a predicted curve to experimental data points and not to an experimental side effect-time curve. To get an insight into nitrendipine plasma concentration side effect relationship we first developed a multiple logistic model to define the most influential demographic, pharmacokinetic, haematologic, haemodynamic and biochemical parameters t for the incidence of side effects. In the second stage a dynamic PK/PD model was developed. 2. Nitrendipine Nitrendipine is a potent calcium entry blocker. It inhibits movement of calcium ions through the voltagesensitive channels of vascular smooth muscles and consequentially causes vasodilatation of large and small arteries [5]. Its main therapeutic effect is a decrease in peripheral vascular resistance with subsequent
2 reduction of blood pressure [5]. It was demonstrated that its pharmacokinetics is very variable due to an extensive first pass metabolism and binding to plasma proteins (98 %). Because of first pass metabolism its bioavailability is low (F = 16 ± 6 %), despite almost complete absorption after peroral application due to high lipophilicity. In the range of therapeutic doses nitrendipine pharmacokinetics is linear. It does not accumulate after multiple dosing with once daily dosing regimen. Nitrendipine is eliminated mainly through liver by biotransformation into inactive and more polar metabolites. The terminal half-life is 10 to 24 hours. Using less sensitive assays the terminal half-life was estimated at lower values (2 to 10 h) [5]. It has been shown that antihypertensive effect of nitrendipine was presented even at plasma concentrations below the limit of quantification. Appearance of its pharmacological effect is in close relationship with its activity at the calcium channels rather than to its plasma concentrations. Nitrendipine causes some mild but quite frequent adverse effects, which usually disappear during continued treatment. The most important and the most frequent adverse effect is headache, which is caused by vasodilatation in the brain. Other common side effects are flushing, palpitations, ankle oedema and dizziness as a consequence of peripheral vasodilatation and increased baroreflex feedback control [5]. 3. Database The database for this study was taken from a blind, randomised, four-way cross over bioequivalence study with a single dose of 20 mg nitrendipine tablet. Forty healthy young male volunteers aged from 18 to 30 years were involved in the study. In each period 16 blood samples were taken from each volunteer at the following times (in hours): 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48. Three hours after drug administration blood pressure was measured in each volunteer. During the period of 48 hours after administration the volunteers were observed for eventual occurrences of side effects. The onset time, duration and severity of side effect was reported. Headache, flush and vertigo occurred in 26 out of 160 applications, headache in 24 applications, flush in 4 applications and vertigo in 1 application. In some applications more than one side effect occurred. The average duration of side effect was 3.3 ± 2.7 h for headache and 0.5 ± 0.1 h for flush and vertigo (mean ± standard deviation). Each volunteer was physically examined and complete laboratory tests were performed. The following parameters were evaluated: age, weight, height, heart rate, systolic (SBP 0 ), and diastolic (DBP 0 ) blood pressure. Among haematological tests counts of erythrocytes, differential leukocytes (neutrophils, eosinophils, basophils, lymphocytes and monocytes) and thrombocytes were assessed, haemoglobin and haematocrite was determined. Among biochemical tests plasma concentrations of chloride, sodium and potassium ions, total proteins, albumin, urea, creatinine, total bilirubin, glucose and total cholesterol were estimated. Plasma levels of alkaline phosphatase (ALP), aspartate transaminase (AST), γ- glutamyltransferase (GGT), and lactate dehydrogenase (LDH) were also determined. All the values of laboratory examinations were in the normal range, but differed among the subjects. Nitrendipine concentrations in plasma samples were determined by GLC-MS. The linear area ranged from 0.1 ng/ml to 20 ng/ml. The limit of quantification was 0.1 ng/ml. 4. Pharmacokinetic analysis Noncompartmental and model dependent pharmacokinetic analysis of individual nitrendipine plasma concentration-time profiles was performed using WinNonLin software (Standard Edition, Version 2.1 Pharsight Corporation). The following noncompartmental PK parameters were identified (mean ± standard deviation): - terminal half-life (t 1/2λz = 9.1 ± 6.5 h), - area under plasma concentration-time curve, by linear trapezoidal method (AUC 0 = 40 ± 31 h ng/ml), - observed maximum plasma concentration (C MAX = 10 ± 7.2 ng/ml), - time when maximum concentration was observed (t MAX = 1.7 ± 0.9 h), - mean residence time (MRT = 7.1 ± 3.1 h), - systemic plasma clearance divided by absolute bioavailability (CL P /F = 14 ± 10 L/min). Obtained parameters are in agreement to the literature data [5]. Large variability in AUC 0 and CL P /F demonstrates that bioavailability is very variable even in relatively homogenous group of healthy men. Nitrendipine pharmacokinetics after oral administration was assessed also using model-dependent approach. Four linear compartment models with first order absorption (one and two-compartment, with and
3 without lag time) were fitted to individual plasma concentration-time profiles. Model parameters were estimated by iterative Gauss-Newton algorithm with Levenberg and Hartley modification. Residual sum of squares was used as a criterion function in the optimisation procedure. Uniform data weighting scheme was applied. Model parameters are summarised in Table 1. Table 1: Estimated pharmacokinetic model parameters (mean ± standard deviation), absorption rate constant k A, elimination rate constant k EL, distribution rate constant from central to peripheral compartment k 12, distribution rate constant from peripheral to central compartment k 21, volume of distribution V D, absolute bioavailability F and absorption lag time t LAG. PK model V D /F [L] k A [h -1 ] k EL [h -1 ] k 12 [h -1 ] k 21 [h -1 ] t LAG [h] one-compartment 2200± ± ±0.20 / / / one-compartment with t LAG 2360± ± ±0.28 / / 0.54±0.43 two-compartment 1850± ± ± ± ±0.24 / two compartment with t LAG 2020± ± ± ± ± ±0.50 The results in Table 1 demonstrate that PK variability of nitrendipine was very high, especially in the absorption rate constant k A. This could be partially attributed to a small number of observations in the absorption phase (in some applications the first data point, t = 0.5 h, was also the concentration maximum). Therefore a bias in k A estimation was taken into account. Validity of each PK model was investigated through determination of Akaike Information Criterion (AIC), Schwarz Criterion (SC) and parameters coefficients of variation (CV). The two-compartment model with lag time of absorption was found as the most adequate, as it had the lowest average values of AIC, SC and CVs. The graphical analysis confirmed this evaluation. This finding coincided with data from the literature [5, 7], where biphasic nitrendipine disposition was proposed [7]. 5. Statistical evaluation SPSS 11.0 (SPSS Inc.) was used for statistical analysis. All data from 160 drug applications were divided into two groups; those, in which side effects occurred (26 applications) and those without side effects (134 applications). Summary statistics of several variables including compartmental and noncompartmental PK parameters were computed. Inter-group comparisons were done using independent samples t-test and Levens F-test was applied for evaluation of homoscedascity. A two-tailed p-value less than 0.05 was considered to be significant. Results of the noncompartmental PK analysis and parameters of the twocompartment model with lag time are presented in Table 2. Table 2: Descriptive statistics of noncompartmental pharmacokinetic parameters and parameters of the twocompartment model with lag time in absorption. noncompartmental PK analysis no side effect AUC 0 [h ng/ml] C MAX [ng/ml] t 1/2λz [h] CL P /F [L/h] t MAX [h] MRT [h] 35.1 ± ± ± ± ± ± 3.1 side effects 8.0 ± 56.6 ± ± ± ± ± p value * * * * model-dependent PK analysis AUC 0 [h ng/ml] C MAX [ng/ml] C MAX /(t MAX - t LAG ) [ng/ml h] C MAX /AUC 0 [h -1 ] t MAX t LAG [h] k A [h -1 ] no side effect 4.4 ± 36.6 ± ± ± ± ± side effects 5.8 ± 54.7 ± ± ± ± ± p value * * * * significant difference (p < 0.05)
4 Values of AUC 0 and C MAX were found to be significantly higher in the group with side effects using noncompartmental and model dependent PK analysis. This finding indicates that increased extent of absorption raised the probability for occurrence of side effects. Parameter C MAX /(t MAX - t LAG ) was used as a measure of the absorption rate. Although it was significantly higher in the group with side effects, other absorption rate parameters (t MAX, t MAX t LAG and k A ) did not differ significantly. This can be attributed to few observations in the absorption phase. Rate of absorption therefore was not reliably estimated. It is therefore possible that also increased absorption rate raises the probability for occurrence of side effects. Comparison of the parameters of the physical examination, laboratory tests and blood pressure measurements revealed significant differences in body height, it was smaller in the group with side effects, p = 0.04; diastolic blood pressure drop 3 hours after drug administration (DBPdiff), it was bigger in the group with side effects, p = 0.04; number of neutrophils, it was smaller in the group with side effects, p = 0.02; number of monocytes, it was smaller in the group with side effects, p = 0.02; number or lymphocytes;it was bigger in the group with side effects, p = 0.04 and total plasma protein concentration, it was smaller in the group with side effects, p = Body height is related to the volume of distribution, therefore increased drug exposure in smaller subjects is expected. Since nitrendipine is highly bound to plasma proteins, total plasma protein concentration affects the concentration of unbound drug and its distribution to the site of action. The influence of diastolic blood pressure drop can be explained by baroreflex feedback mechanism, which is controlling blood pressure. Rapid drop of blood pressure results in incresed heart rate. 6. Multiple logistic regression To be able to predict the occurrence of side effects multiple logistic regression models were built, based on a set of predictor variables of the physical examination laboratory tests and noncompartmental PK parameters. Models were estimated by block entry of variables using the SPSS method ENTER and a stepwise forward conditional method (FSC). In the second method - FSC (p 1, p 2 ) each predictor variable was included in the regression model only if its starting significance level was less than p 1 and if during regression it did not exceed p 2. Six logistic regression models were built. They included observed systolic and diastolic blood pressures (BP) or drops in systolic and diastolic blood pressures (BPdiff): - Enter, [BP], - Enter, [Bpdiff], - FSC (0.1, 0.2), [BP], - FSC (0.1, 0.2), [BPdiff], - FSC (0.2, 0.4), [BP], - FSC (0.2, 0.4), [BPdiff]. This way the most influential predictor variables for occurrence of side effects were identified. Results are summarised in Table 3. Table 3: Learning errors (L.E.) of the six different logistic regression models and a list of the most influential parameters. logistic models Enter [BP] Enter [Bpdiff] FSC (0.1, 0.2) [BP] FSC (0.1, 0.2) [BPdiff] FSC (0.2, 0.4) [BP] FSC (0.2, 0.4) [BPdiff] L.E. 9.4 % 10.1 % 13.8 % 13.2 % 13.8 % 11.3 % AUC 0 (+), AUC t MAX ( ), t MAX ( ), 0 (+), AUC K influential ( ), Na + AUC (+), 0 (+), 0 (+), height ( ), K + ( ), Na + (+), Na AUC 0 (+), AUC 0 (+), (+), LDH ( ), height ( ), total prot. ( ), total prot. ( ), tot. prot. ( ), parameters SBP 3 (+), SBPdiff (+), total prot. ( ), lymphocyt. (+), lymphocyt. (+), lymph. (+), DBP 3 (+) DBPdiff ( ) lymphocyt. (+) DBP 0 (+) DBP 0 (+) gluc. ( ), erytr. (+), DBPdiff ( ) (+) and ( ) denotes a positive or negative value of a regression coefficient Again higher value of AUC 0 indicated higher probability for the occurrence side effect. The influence of increased absorption rate (smaller t MAX ) was also observed. Again the effect of total plasma protein concentration, body height, and count of lymphocytes was evident. Moreover logistic regression revealed
5 the importance of plasma concentrations of sodium and potassium ions. These ions are the main body electrolytes and act on cell s resting membrane potential. Higher sodium and a lower potassium plasma concentration results in increased sensitivity of target cells to nitrendipine. To test the predictive capability of the logistic regression models the database was split to a learning set of randomly selected 112 applications (18 with side effect and 94 without) and a test set of 48 applications (8 with side effect and 40 without). This cross validation procedure was repeated three times (group I to III) choosing three different learning and testing sets. Learning (L.E.) and prediction (P.E.) errors for all the models are summarised in Table 4. Table 4: Learning and prediction errors for multiple logistic regression models. logistic models Enter Enter FSC (0.1, FSC (0.1, FSC (0.2, FSC (0.2, 0.4) [BP] [Bpdiff] 0.2) [BP] 0.2) [Bpdiff] 0.4) [BP] [BPdiff] L.E. for I. group 0 % / * 13 % 13 % 9 % 9 % L.E. for II. group 0 % 5 % 14 % 14 % 10 % 12 % L.E. for III. group 5 % 5 % 14 % 14 % 11 % 11 % mean 2 % 5 % 14 % 14 % 11 % 11 % P.E. for I. group 42 % / * 27 % 27 % 31 % 31 % P.E. for II. group 38 % 31 % 12 % 17 % 17 % 19 % P.E. for III. group 23 % 21 % 15 % 17 % 25 % 25 % mean 34 % 26 % 18 % 20 % 24 % 25 % * no convergence was achieved Learning errors were between 0 and 14 %, while prediction errors were between 12 and 42 %. Models based on block entry of variables (Enter) had the lowest learning errors and the biggest prediction errors. The best model for prediction of side effects was FSC (0.1, 0.2) [BP]. 7. PK/PD link model For the PK part of the link model already established two-compartment PK model with lag time (2-comp.+ t LAG ) was used. Fixed effect (logistic) model was used to relate nitrendipine concentration to the probability of side effect. This model is based on a side effect threshold concentration. The probability of the side effect (p) is then calculated as p = c N /(ec 50 N + c N ) equation 1, where c is a concentration of a drug and ec 50 is the concentration that produces a 50 % probability that the effect occurred. Parameter N denotes a slope of probability versus concentration curve [6]. In our case a time delay between maximum plasma concentration and appearance of side effect was observed (Figure 1), which resulted in a hysteresis in a side effect versus plasma concentration plot. For the side effects flush and vertigo little or no hysteresis was observed. Furthermore the duration and the onset of the headache differed from the other two side effects considerably. Therefore PK/PD model parameters were estimated only for the headache time courses. Due to the observed hysteresis indirect link model was established. This link model included additional, hypothetical compartment; an effect compartment (EC). The drug concentrations in effect compartment (C E ) represented the drug concentrations at the effect site, which were related to the probability of side effect. Time delay between side effect occurrence and plasma drug concentration was modelled as a first order distribution of a drug from plasma to the effect compartment (rate constant k EO ). A PK/PD model is schematically presented in Figure 2. Six PK parameters (V D /F, k A, k EL, k 12, k 21, and t LAG ) that were already estimated were set as individual constraints. Two different procedures were used to fit the three PK/PD model parameters (k EO, ec 50, and N) to the observed headache-time courses in each of the 24 applications with side effect. Firstly the parameters were estimated using WinNonLin. Continuously observed headache-time data were transformed to equally spaced discrete data at time intervals of 0.1 h. The estimation of N depended on initial values and it tended to higher values to get a better fit. In a second procedure a custom spreadsheet in Excel was developed, where the N was set to 300, as this was the highest possible value for which the expression (C E ) N could be computed. Parameter k EO was evaluated by solving the equation C E (t START ) = C E (t END ). The concentration in the EC (C E ) at the onset of headache is equal to the concentration in EC at the termination of headache in order to get the best fit. Moreover these concentrations also equalled ec 50 (figure 1). Since the values for N were high in order to get steep and momentary onset of probability of headache (left bottom graph in figure 2), population value for N (n ) was calculated as n 4/SQRT(var(lnec 50 ) 2π). The expression var(lnec 50 ) denotes a variance of lognormal distribution of ec 50 and n denotes a slope of a cumulative curve of
6 lognormal distribution of individual ec 50. These estimates were comparable to those obtained by WinNonLin (Table 5). Nitrendipine concentration [ng/ml] Time [h] Probability of headache ABSORPTION 20 mg nitrendipine k A 1 t LAG 2 PERIPHERAL COMPARTMENT k 12 k 21 CENTRAL COMPARTMENT lnc P k EO V D /F C E (t) EFFECT COMPARTMENT p Ν ec 50 C E t 1 k EL k EO E L I M I N A T I O N headache t Figure 1. PK/PD model response (dash-dotted curve) for a representative application with headache. Pharmacokinetic model (2-comp.+ t LAG ) response (solid curve), concentration in the effect compartment (dashed curve). The observed plasma concentrations (dots), observed headache (grey area). The PK model response was obtained by WinNonLin. The presented PK/PD model response and C E were calculated in Excel. Figure 2. A diagram of the overall PK/PD model. The upper part represents a PK model with parameters V D /F, k A, k EL, k 12, k 21, and t LAG. In central compartment the observed plasma concentrations (C P ) are drawn. The lower part presents PD model parameters (k EO, ec 50, and N) that were estimated. In right bottom graph pharmacodynamic data are drawn. The aim of the PK/PD model was to get the concentrations in EC (C E ) and to get the pharmacodynamic curve (left bottom graph), where p is a probability for occurrence of headache. Table 5: Means and standard deviations of the pharmacodynamic parameters estimated by WinNonLin and an Excel spreadsheet. n k EO [h -1 ] ec 50 [ng/ml] Estimates in WinNonLin ± ± 1.9 Estimates in EXCEL ± ± 2.2 Population values for each of the three PK/PD model parameters were estimated using nonlinear regression in SPSS. The PK/PD model was fitted to discrete headache-time courses (intervals of 0.05 h) for all of 158 applications in a single step. The two applications in which only flush and vertigo occurred were not included. Parameters of the subpopulation of 24 applications with headache were also evaluated in order to compare them with the average values of the previously estimated parameters. The subpopulation value of N estimated in SPSS is compared to previously determined n. The results are shown in Figure 3.
7 p concentration in the effect compartment [ng/ml] Figure 3. Vertical lines denote individual pharmacodynamic curves (estimated in MS EXCEL) for each of all 24 applications that had the headache. A thick curve represents the subpopulation curve calculated on equation 1 using average value of the ec 50 (estimated by MS EXCEL) and using n as N. The thick curve also represents a cumulative lognormal distribution of individual values of ec 50. The other two curves were also calculated by equation 1 using subpopulation (dashed curve) and population (thin curve) values for N and ec 50 that were estimated with the SPSS. The thick and the dashed curves were expected to overlap as they both represent a subpopulation with headache. This discrepancy can be explained by a strong positive correlation between N and ec 50. A higher value of N that was set in Excel calculations resulted in lower values of ec 50 and movement of the thick curve to the left. Even though considerable difference between population and subpopulation curves was found (the dashed and the thin curve). Subpopulation and population values for ec 50 were 6.62 ± 0.22 ng/ml and 39.8 ± 2.5 ng/ml, respectively. Here it must not be forgotten that our data is based on healthy young male population and the absolute values should not be extrapolated. As the difference was significant we concluded that the headache was occurred also due to the individual s increased sensitivity (lower ec 50 ) to nitrendipine concentration at the site of action. 8. Conclusions The aim of the modelling was to relate nitrendipine side effects to the pharmacokinetic and pharmacodynamic properties of this drug. This was done in two mayor steps. First only the presence of side effects was taken into account. Here the reasons for presence of side effects were established using some statistical tools. An increased extent and rate of absorption as well as an increased sensitivity to nitrendipine at the site of action were found to expand the probability for side effects (headache, flush and vertigo). A PK/PD model was fitted to side-effects-time courses. A two-compartment PK model with lag time and fixed effect PD model were indirectly linked into PK/PD model. Individual and population values of the PD parameters were evaluated. Differences in population and subpopulation values of ec 50 confirmed that side effects partly occurred due to increased sensitivity to nitrendipine. The developed methodology could supply useful criteria for the design of optimal drug dosage regimen, moreover it offers possibility for selecting individuals with high probability for adverse drug reactions. 9. References References: 1. Bolton, S., Pharmaceutical Statistics: Practical and Clinical Applications. 3 rd Ed., Marcel Dekker, Inc, New York, Breimer, D.D. and Danhof, M., Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development. Clinical Pharmacokinetics, 32 (1997),
8 3. Derendorf, H. and Meibohm, B., Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives. Pharmaceutical Research, 16 (1999), Gabrielsson, J. and Weiner, D., Pharmacokinetic and Pharmacodynamic Data Analysis; Concepts and Applications. 3 rd Ed., Swedish Pharmaceutical Society, Stockholm, 2000, Goa, K.L. and Sorkin, E.M., Nitrendipine A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in the Treatment of Hypertension. Drugs, 33 (1987), Hung, O.R., et al., Thiopental Pharmacodynamics II. Quantitation of Clinical and Electroencephalographic Depth of Anesthesia. Anesthesiology, 77 (1992), Raemsch, K.D. and Sommer, J., Pharmacokinetics and metabolism of nitrendipine. In: Nitrendipine, (Eds.: Scriabne et al), Urban and Schwarzenberg, 1984, Welling, P.G., Pharmacokinetics: Processes, Mathematics, and Applications. 2 nd Ed., American Chemical Society, Washington, DC, WinNonLin User s Guide, Scientific Consulting, Inc., 1997.
BASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationSponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance:
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods:
Study No: MNK111587 Title : A healthy volunteer repeat dose study to evaluate; the safety, tolerability, pharmacokinetics, effects on the pharmacokinetics of midazolam and the neurokinin-1 (NK1) receptor
More informationFlecainide pharmacokinetics in healthy volunteers: the influence of urinary ph
Br. J. clin. Pharmac. (1985), 20, 333-338 Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph A. JOHNSTON, S. WARRNGTON' & P. TURNER Department of Clinical Pharmacology, St Bartholomew's
More informationNoncompartmental Analysis (NCA) in PK, PK-based Design
Noncompartmental Analysis (NCA) in PK, PK-based Design Helmut Schütz BEBAC Consultancy Services for Bioequivalence and Bioavailability Studies 17 Vienna, Austria helmut.schuetz@bebac.at Bioequivalence
More informationJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,
More informationOnline Supplementary Appendix
Online Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lehman * LH, Saeed * M, Talmor D, Mark RG, and Malhotra
More informationTutorial. & In case studies 1 and 2, we explore intravenous iv. & Then, we move on to extravascular dosing in case
The AAPS Journal, Vol. 1, No. 1, January 2016 ( # 2015) DOI: 10.120/s1224-015-917-6 Tutorial Pattern Recognition in Pharmacokinetic Data Analysis Johan Gabrielsson, 1,4 Bernd Meibohm, 2 and Daniel Weiner
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationUnit 1 Exploring and Understanding Data
Unit 1 Exploring and Understanding Data Area Principle Bar Chart Boxplot Conditional Distribution Dotplot Empirical Rule Five Number Summary Frequency Distribution Frequency Polygon Histogram Interquartile
More informationEvaluation Report of the Pneumatic Tube Transport System (PEVCO) connecting Dialysis Hospital to. Mubarak Hospital. Dr.
5 Evaluation Report of the Transport System (PEVCO) connecting Dialysis Hospital to Mubarak Hospital Dr. Anwar AlAnjeri Senior Registrar Clinical Biochemistry Laboratory Mubarak Hospital Introduction:
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationRenal Impairment From Dettli to Guideline: What can we learn?
Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationPAGE Meeting 2003 Verona, Italy
PAGE Meeting 2003 Verona, Italy Population pharmacokinetics/-dynamics of the direct thrombin inhibitor dabigatran in patients undergoing hip replacement surgery J. Stangier 1, K.H. Liesenfeld 1, C. Tillmann
More informationCRITERIA FOR USE. A GRAPHICAL EXPLANATION OF BI-VARIATE (2 VARIABLE) REGRESSION ANALYSISSys
Multiple Regression Analysis 1 CRITERIA FOR USE Multiple regression analysis is used to test the effects of n independent (predictor) variables on a single dependent (criterion) variable. Regression tests
More informationPHAR 7633 Chapter 20 Non Compartmental Analysis
Student Objectives for this Chapter PHAR 7633 Chapter 20 Non Compartmental Analysis To understand and use the non compartmental approach to parameter estimation be able to define, use, and calculate the
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More informationPharmacokinetics of drug infusions
SA Hill MA PhD FRCA Key points The i.v. route provides the most predictable plasma concentrations. Pharmacodynamic effects of a drug are related to plasma concentration. Both plasma and effect compartments
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationLack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids
Blackwell Science, Ltdxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254riginal Articleseltamivir and antacids lack of kinetic interactionp. Snell et al. Lack of pharmacokinetic
More informationThe pharmacokinetics and dose proportionality of cilazapril
Br. J. clin. Pharmac. (1989), 27, 199S-204S The pharmacokinetics and dose proportionality of cilazapril J. MASSARELLA, T. DEFEO, A. LIN, R. LIMJUCO & A. BROWN Departments of Drug Metabolism and Clinical
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationCHMP Type II variation assessment report
15 November 2012 EMA/CHMP/549534/2012 Committee for Medicinal Products for Human Use (CHMP) CHMP Type II variation assessment report Micardis, Pritor, Kinzalmono Procedure No. EMEA/H/C/xxxx/WS/0254 Worksharing
More informationEvaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t last (Common)
Drug Development Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t last (Common) The Journal of Clinical Pharmacology 2016, 56(7) 794 800 C 2015, The Authors.
More informationClinical Pharmacology. Pharmacodynamics the next step. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand
1 Pharmacodynamic Principles and the Course of Immediate Drug s Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand The time course of drug action combines the principles
More informationPharmacokinetics and pharmacodynamics of inhaled corticosteroids
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids H. Derendorf, PhD, a G. Hochhaus, PhD, a B. Meibohm, PhD, a H. Möllmann, MD, b and J. Barth, MD b Gainesville, Fla., and Bochum, Germany
More informationIAPT: Regression. Regression analyses
Regression analyses IAPT: Regression Regression is the rather strange name given to a set of methods for predicting one variable from another. The data shown in Table 1 and come from a student project
More informationBioavailability and Pharmacokinetics of Isradipine after Oral and Intravenous Administration: Half-Life Shorter than Expected?
C Pharmacology & Toxicology 2000, 86, 178 182. Printed in Denmark. All rights reserved Copyright C ISSN 0901-9928 Bioavailability and Pharmacokinetics of Isradipine after Oral and Intravenous Administration:
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationTime to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect
Adjustment of k e0 to Reflect True Time Course of Drug Effect by Using Observed Time to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect Algorithm Reported by Shafer and
More informationTables of Normal Values (As of February 2005)
Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal
More informationPHARMACOKINETICS OF DRUG ABSORPTION
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Applied Biopharmaceutics & Pharmacokinetics > Chapter 7. Pharmacokinetics of Oral Absorption >
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBD
CT Registry ID#5286 Page 1 Summary ID# 5286 Clinical Study Summary: Study B4Z-JE-LYBD An Open Label, Dose-Titration Safety Study of Hydrochloride in Outpatient Japanese Children with Attention-Deficit/Hyperactivity
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationSYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22
SYNOPSIS Title of the study: A randomized, cross-over, open, euglycemic clamp study on the relative bioavailability and activity of 0.6 U/kg insulin glargine and 20 µg lixisenatide, given as on-site mix
More informationNoncompartmental Analysis (NCA) in PK, PK-based Design
Noncompartmental Analysis (NCA) in PK, PK-based Design Helmut Schütz BEBAC Bioequivalence and Bioavailability, Pre-Conference Workshop Ljubljana, 17 May 21 1 54 Bioequivalence History Surrogate of clinical
More informationSupplementary materials
Supplementary materials Table S Adverse events identified by participants diary logs and blood hematologic and biochemical tests (n=2) group (n=) Placebo group (n=) P value for chi-squared test Asthma
More informationCase Study in Placebo Modeling and Its Effect on Drug Development
Case Study in Placebo Modeling and Its Effect on Drug Development Modeling and Simulation Strategy for Phase 3 Dose Selection of Dasotraline in Patients With Attention-Deficit/Hyperactivity Disorder Julie
More informationCOMPARTMENTAL ANALYSIS OF DRUG DISTRIBUTION Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program September 23, 2010
COMPARTMENTAL ANALYSIS OF DRUG DISTRIBUTION Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program September 23, 2010 Office of Clinical Research Training and Medical Education National
More informationC OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:
LESSON 2 Basic Pharmacokinetics C OBJECTIVES After completing Lesson 2, you should be able to: 1. Define the concept of apparent volume of distribution and use an appropriate mathematical equation to calculate
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationNORMAL LABORATORY VALUES FOR CHILDREN
Pediatric Drug Lookup Normal Laboratory Values for NORMAL LABORATORY VALUES FOR CHILDREN CHEMISTRY Normal Values Albumin 0-1 y 2.0-4.0 g/dl 1 y to adult 3.5-5.5 g/dl Ammonia Newborns 90-150 mcg/dl 40-120
More informationSponsor: Sanofi Drug substance(s): GZ316455
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationClinician Blood Panel Results
Page 1 of 7 Blood Panel - Markers Out of Range and Patterns (Pattern: proprietary formula using one or more Blood Markers) Blood Panel: Check for Markers that are out of Lab Range ***NOTE*** Only one supplement
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationNEW RCPCH REFERENCE RANGES-
s vary between populations and age groups and it is important to always check the reference Haematology: Haemoglobin Male 130 175 g/l 0 6 days 145-220 g/l Female 115 165 g/l 7 days 140-186 g/l 8 days 3
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationWHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION
PHARMACOKINETICS I Absorption & Distribution LEARNING OUTCOMES By the end of the lecture students will be able to.. Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/08/21) Define pharmacokinetics,
More informationMODEL-BASED DOSE INDIVIDUALIZATION APPROACHES USING BIOMARKERS
MODEL-BASED DOSE INDIVIDUALIZATION APPROACHES USING BIOMARKERS CATHERINE M SHERWIN PAGE 27 th Meeting, Montreux, Switzerland 30 th May 2018 Division of Clinical Pharmacology, Pediatrics, School of Medicine
More informationDevelopment of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization
Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization Nico Holmstock Scientist, Janssen R&D M CERSI 2017, BALTIMORE (USA) Canagliflozin An
More informationSupplementary Note Details of the patient populations studied Strengths and weakness of the study
Supplementary Note Details of the patient populations studied TVD and NCA patients. Patients were recruited to the TVD (triple vessel disease) group who had significant coronary artery disease (defined
More informationChapter 11: Advanced Remedial Measures. Weighted Least Squares (WLS)
Chapter : Advanced Remedial Measures Weighted Least Squares (WLS) When the error variance appears nonconstant, a transformation (of Y and/or X) is a quick remedy. But it may not solve the problem, or it
More informationThe general Concepts of Pharmacokinetics
The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl
More informationChapter 1: Exploring Data
Chapter 1: Exploring Data Key Vocabulary:! individual! variable! frequency table! relative frequency table! distribution! pie chart! bar graph! two-way table! marginal distributions! conditional distributions!
More informationPKPD modelling to optimize dose-escalation trials in Oncology
PKPD modelling to optimize dose-escalation trials in Oncology Marina Savelieva Design of Experiments in Healthcare, Issac Newton Institute for Mathematical Sciences Aug 19th, 2011 Outline Motivation Phase
More informationModified Release: C min C τ. Modified Release
Wikimedia Commons 2007 Sokoljan Creative Commons Attribution-ShareAlike 3.0 Unported Modified Release: C min C τ Modified Release C C min C τ Helmut Schütz BEBAC 1 24 Another Reminder Rose is a rose is
More informationIRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationPharmacokinetics of ibuprofen in man. I. Free and total
Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships Ibuprofen kinetics were studied in 15 subjects after four oral doses. Plasma levels of both total and free ibuprofen were
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGeneral Chemistry Scheme Guide
General Chemistry Scheme Guide Copyright WEQAS. All rights reserved. No part of this document may be reproduced or utilised in any form without permission from WEQAS Contents. Scheme details and repertoire.....
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationModel-based quantification of the relationship between age and anti-migraine therapy
6 Model-based quantification of the relationship between age and anti-migraine therapy HJ Maas, M Danhof, OE Della Pasqua Submitted to BMC. Clin. Pharmacol. Migraine is a neurological disease that affects
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Perfan Injection 100 mg/20 ml Concentrate for Solution for Injection Active substance: enoximone Read all of this leaflet carefully before you
More informationGuideline for Bioequivalence Studies of Generic Products
English translation of Attachment 1 of Division-tification 0229. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012 Guideline for Bioequivalence Studies of Generic Products Index
More informationPharmacokinetics and allometric scaling of levormeloxifene, a selective oestrogen receptor modulator
BIOPHARMACEUTICS & DRUG DISPOSITION Biopharm. Drug Dispos. 24: 121 129 (2003) Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/bdd.344 Pharmacokinetics and allometric scaling
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Spire Portsmouth Hospital Bartons Road Havant PO9 5NP United Kingdom Contact: Natalie Peck E-Mail: natalie.peck@spirehealthcare.com Website:
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationPOPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development
POPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development Definition Population Pharmacokinetics Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationBiomath M263 Clinical Pharmacology
Training Program in Translational Science Biomath M263 Clinical Pharmacology Spring 2013 www.ctsi.ucla.edu/education/training/webcasts Wednesdays 3 PM room 17-187 CHS 4/3/2013 Pharmacokinetics and Pharmacodynamics
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationTitle: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations
1 SUPPLEMENTARY MATERIALS 2 3 4 5 6 7 8 Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two Phase 2 clinical trials Authors: Radojka M. Savic,
More informationDelta Check Calculation Guide
Delta Check Calculation Guide National Technology 2017, All Rights Reserved By Senior Scientific Researcher, Asmaa Taher Table of Contents Definition... 2 Purpose... 2 Delta Check Research Studies... 2
More informationSupplementary Online Content
Supplementary Online Content Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559. eequation. Applying the
More informationIndividual Study Table Referring to Part of the Dossier. Page:
2. SYNOPSIS Title of Study: A comparative study of the pharmacokinetic/pharmacodynamic and safety profiles of extended release, regular release and placebo during a 12 hour observation in post-extraction
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationMMI 409 Spring 2009 Final Examination Gordon Bleil. 1. Is there a difference in depression as a function of group and drug?
MMI 409 Spring 2009 Final Examination Gordon Bleil Table of Contents Research Scenario and General Assumptions Questions for Dataset (Questions are hyperlinked to detailed answers) 1. Is there a difference
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOsnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,
Osnove farmakokinetike Aleš Mrhar Prirejeno po A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne, College of Pharmacy, University of Oklahoma Pharmacokinetics/Pharmacodynamics Pharmacodynamics
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationROTUNDA HOSPITAL DEPARTMENT OF LABORATORY MEDICINE
This active test table informs the user of Biochemistry tests available in house. s referred to other sites are recorded in the Referred Table. Issue date: 4 TH April 2016 Contact Phone Number ext.1345/2522
More informationPharmacodynamic principles and the time course of immediate drug effects
TCP 2017;25(4):157-161 http://dx.doi.org/10.12793/tcp.2017.25.4.157 Pharmacodynamic principles and the time course of immediate drug effects TUTORIAL Department of Pharmacology & Clinical Pharmacology,
More information